Peer AI - Medical Writing Platform for FDA Submissions - Life Sciences Today Podcast Episode 63

Why It Matters

By slashing regulatory drafting time and improving submission quality, Pure AI accelerates drug approvals, lowering costs and bringing life‑changing therapies to patients faster.

Key Takeaways

• Pure AI automates FDA submission documents using specialized AI agents.
• Platform reduces drafting time by up to 90% while improving quality.
• AI predicts regulatory queries, enabling proactive issue resolution.
• Human-in-the-loop checkpoints ensure compliance and expert oversight throughout.
• Faster, higher-quality submissions accelerate patient access to therapies.

Summary

The Life Sciences Today podcast featured Anita Modi, founder and CEO of Pure AI, unveiling the company’s AI‑driven platform that automates the creation and management of FDA regulatory documents. After starting as a medical‑writing drafting tool, Pure AI now offers a suite of autonomous agents that ingest data, map templates, author content, and perform quality checks across the entire submission workflow.

Modi highlighted the industry’s chronic bottleneck: roughly 1,500 unique documents per drug, spanning up to 200,000 pages, with manual processes causing frequent errors and delays. By orchestrating six specialized AI agents per document, Pure AI claims 50‑90% time savings and a measurable uplift in submission quality, addressing the fact that about one‑third of FDA filings contain quality issues and 75% experience delays, often averaging 435 days.

She cited concrete results: phase‑3 clinical study reports and IND modules see up to 90% faster drafting, while safety narratives and protocols achieve similar gains without sacrificing accuracy. The platform also leverages predictive analytics to flag potential regulator queries before they arise, turning a traditionally reactive resubmission cycle into a proactive, iterative process.

The broader implication is a reshaping of the medical‑writing function—from repetitive drafting to strategic oversight—while accelerating drug‑to‑market timelines and reducing development costs. Pure AI’s approach demonstrates how tightly coupled human expertise and generative AI can streamline compliance, improve patient access, and set a new efficiency benchmark for the life‑sciences industry.

Original Description

We're excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Anita Modi, Co-Founder and CEO at Peer AI. Peer AI is a medical writing acceleration tool for pharma/biotech regulatory teams, now repositioning as a "submission platform." The authoring piece is the real product — the orchestration and prediction layers are newer and almost certainly less mature. The April 14, 2026, press release announcing they're "now a platform" is the tell: two weeks ago, they were a document-drafting tool, and the Command Center + query prediction capabilities are fresh additions being marketed ahead of their maturity curve.

The core wedge is medical writer productivity on large clinical documents for IND/NDA/BLA submissions. Every single attributed quote on their site is from a medical writer, head of medical writing, or regulatory VP — not from CMOs, not from heads of regulatory strategy, not from CEOs. That's diagnostic. The buyer is a Head of Medical Writing at a mid-to-large biotech or pharma who is drowning in CSR and protocol drafts and can justify a tool that cuts 40-day drafts to 17.

For more great episodes of our Life Sciences Today Podcast, check out: https://www.healthcareittoday.com/category/life-sciences-today-podcasts/